Whole Body CT Doesn't Cut Mortality in Peds Blunt Trauma

Share this content:
Whole Body CT Doesn't Cut Mortality in Peds Blunt Trauma
Whole Body CT Doesn't Cut Mortality in Peds Blunt Trauma

TUESDAY, April 10, 2018 (HealthDay News) -- Whole body computed tomography (WBCT) is not associated with reduced mortality compared with a selective CT approach among children with blunt trauma, according to a study published online April 9 in JAMA Pediatrics.

James A. Meltzer, M.D., from the Albert Einstein College of Medicine in Bronx, N.Y., and colleagues conducted a retrospective multicenter cohort study involving data from children aged 6 months to 14 years with blunt trauma who received an emergent CT scan in the first two hours after arrival at the emergency department. Patients who received CT head, chest, and abdomen/pelvis scans were classified as having WBCT, while those who did not receive all three scans were classified as having selective CT; data were included for 42,912 children.

The researchers found that 20.4 percent of the children received a WBCT. Within seven days, 0.9 percent of the children died. There was no significant difference in mortality for children who received WBCT versus those who received selective CT, after adjustment for propensity score (absolute risk difference, −0.2 percent; 95 percent confidence interval, −0.6 to 0.1 percent). There were no significant associations between WBCT and mortality in subgroup analyses.

"Among children with blunt trauma, WBCT, compared with a selective CT approach, was not associated with lower mortality," the authors write. "These findings do not support the routine use of WBCT for children with blunt trauma."

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »